Enlivex Therapeutics Ltd. (ENLV.TA)
ILA 337.5
(2.09%)
ILA 337.5
(2.09%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.74 Million USD | -37.53% |
| 2022 | 10.8 Million USD | 6.87% |
| 2021 | 10.1 Million USD | 107.49% |
| 2020 | 4.87 Million USD | -22.41% |
| 2019 | 6.27 Million USD | 372.74% |
| 2018 | 1.32 Million USD | 188.7% |
| 2017 | 460 Thousand USD | -76.18% |
| 2016 | 1.93 Million USD | -25.27% |
| 2015 | 2.58 Million USD | 13.33% |
| 2014 | 2.28 Million USD | 1640.46% |
| 2013 | 131 Thousand USD | 61.73% |
| 2012 | 81 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.34 Million USD | -20.4% |
| 2024 Q1 | 4.19 Million USD | -37.81% |
| 2023 FY | 6.74 Million USD | -37.53% |
| 2023 Q1 | 9.44 Million USD | -12.53% |
| 2023 Q4 | 6.74 Million USD | -17.29% |
| 2023 Q3 | 8.15 Million USD | -6.17% |
| 2023 Q2 | 8.69 Million USD | -7.99% |
| 2022 Q3 | 9.14 Million USD | 3.22% |
| 2022 Q4 | 10.8 Million USD | 18.17% |
| 2022 FY | 10.8 Million USD | 6.87% |
| 2022 Q1 | 10.96 Million USD | 8.53% |
| 2022 Q2 | 8.85 Million USD | -19.27% |
| 2021 Q2 | 4.98 Million USD | -7.02% |
| 2021 FY | 10.1 Million USD | 107.49% |
| 2021 Q1 | 5.35 Million USD | 9.98% |
| 2021 Q4 | 10.1 Million USD | 0.23% |
| 2021 Q3 | 10.08 Million USD | 102.45% |
| 2020 Q2 | 5.24 Million USD | -6.21% |
| 2020 FY | 4.87 Million USD | -22.41% |
| 2020 Q3 | 4.87 Million USD | -7.09% |
| 2020 Q4 | 4.87 Million USD | -0.04% |
| 2020 Q1 | 5.59 Million USD | -10.93% |
| 2019 Q3 | 5.43 Million USD | -0.62% |
| 2019 FY | 6.27 Million USD | 372.74% |
| 2019 Q4 | 6.27 Million USD | 15.53% |
| 2019 Q2 | 5.46 Million USD | -2.18% |
| 2019 Q1 | 5.59 Million USD | 320.93% |
| 2018 Q2 | 144 Thousand USD | 0.0% |
| 2018 Q3 | 960 Thousand USD | 566.67% |
| 2018 Q4 | 1.32 Million USD | 38.33% |
| 2018 FY | 1.32 Million USD | 188.7% |
| 2018 Q1 | - USD | -100.0% |
| 2017 FY | 460 Thousand USD | -76.18% |
| 2017 Q3 | 537 Thousand USD | -32.2% |
| 2017 Q4 | 460 Thousand USD | -14.34% |
| 2017 Q1 | 1.61 Million USD | -16.21% |
| 2017 Q2 | 792 Thousand USD | -51.05% |
| 2016 Q3 | 1.99 Million USD | 36.17% |
| 2016 Q2 | 1.46 Million USD | -36.17% |
| 2016 Q1 | 2.3 Million USD | -10.99% |
| 2016 FY | 1.93 Million USD | -25.27% |
| 2016 Q4 | 1.93 Million USD | -3.4% |
| 2015 Q3 | 1.81 Million USD | 2.55% |
| 2015 Q4 | 2.58 Million USD | 42.53% |
| 2015 FY | 2.58 Million USD | 13.33% |
| 2015 Q2 | 1.76 Million USD | 0.91% |
| 2015 Q1 | 1.75 Million USD | -23.16% |
| 2014 Q4 | 2.28 Million USD | 98.95% |
| 2014 Q3 | 1.14 Million USD | 60.28% |
| 2014 Q2 | 715 Thousand USD | 0.0% |
| 2014 FY | 2.28 Million USD | 1640.46% |
| 2013 Q4 | 131 Thousand USD | 0.0% |
| 2013 FY | 131 Thousand USD | 61.73% |
| 2012 FY | 81 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Matricelf Ltd | 3.7 Million ILA | -82.351% |